Breast Augmentation

What breast augmentation is (and is not)

Breast augmentation increases breast volume and shape using either silicone gel implants, saline implants, or autologous fat transferred from another body region (fat grafting). The implant-based procedures are the dominant approach globally and in Korea; fat-grafting-only is a smaller subset of cases for patients seeking modest enhancement without implant placement.

Implant categories in current Korean practice:

• Cohesive silicone gel implants — the global standard. The gel is cross-linked to a cohesive consistency that holds shape if the shell ruptures, dramatically improving the rupture safety profile vs. older liquid-silicone implants. Subcategories include round vs. anatomical (teardrop), smooth shell vs. nanotextured (Motiva SmoothSilk) vs. textured shells from prior generations.
• Saline implants — silicone shell filled with saline solution after placement. Still in use, particularly in cases with strong tissue cover or for patients preferring the saline option. Less natural feel than cohesive gel; rupture leads to deflation and saline absorption (saline absorbs harmlessly).
• Hybrid approaches — implant + supplemental fat grafting in the same operation to soften the upper-pole transition, particularly relevant for very-thin patients or revision cases.

Placement positions:

• Subglandular (above pectoral muscle) — implant placed between glandular tissue and pectoralis. Reserved for cases with strong tissue cover; produces more direct upper-pole projection but greater visibility risk in thin patients.
• Subfascial — placement under the pectoral fascia but above the muscle. A middle option used in specific cases.
• Dual-plane (partial submuscular) — upper pole of the implant under the pectoralis, lower pole subglandular. The most common Korean placement for moderate tissue thickness; balances natural upper-pole transition with adequate cover.
• Submuscular (full) — full coverage by the pectoralis. Reserved for very-thin patients or specific revision scenarios. Produces more upper-pole flatness and animation deformity (visible distortion when chest is flexed).

Incision approaches:

• Inframammary (under the breast crease) — the most common Korean primary access. Best visualization for pocket creation and hemostasis. Scar hidden in the natural fold.
• Periareolar (around lower nipple edge) — used in specific cases. Scar generally well-hidden in nipple-areola transition. Slightly higher reported rates of breastfeeding interference.
• Transaxillary (under-arm endoscopic) — used selectively for patients prioritizing breast scarlessness. Trades off visualization, pocket precision, and revision-surgery convenience.
• TUBA (transumbilical) — implant inserted via belly-button. Largely obsolete; only saline implants can be inserted via this route, and visualization is limited.

Breast augmentation is not a substitute for breast lift (mastopexy). Patients with significant ptosis (sag) need a lift to address position, with augmentation often combined in the same operation. Augmentation alone in a significantly ptotic breast produces a bottoming-out, oddly-positioned result.

Breast augmentation is also not the right answer for patients seeking dramatic asymmetry correction or significant size reduction. Reduction mammoplasty is a different procedure; symmetry correction sometimes requires more complex combinations of implant + reduction + lift to address.

What patients actually report

Our reviews database holds limited Korean-clinic breast augmentation entries directly tagged. Patterns below are aggregated from international forums (RealSelf BA boards, Reddit r/PlasticSurgery, BellaOnline), Korean platforms, and peer-reviewed satisfaction literature on primary augmentation.

Volume regret pattern is bimodal across markets. US-market reviewers more frequently report wishing they had gone larger; Korean-market reviewers more frequently report being satisfied with their initial volume choice or occasionally wishing they had gone smaller. The aesthetic frame and surgeon counseling at consultation are the primary drivers; international patients arriving in Korea with US-calibrated volume preferences should be prepared for surgeon push-back on volumes the Korean assessment considers excessive for their tissue cover.

The drop-and-fluff timeline is the most-misunderstood part of recovery. Patients judging their result at 4–6 weeks frequently describe it as too high-set, too firm, or otherwise unsatisfactory. Reviewers whose consultation explicitly walked through the 3–6 month settlement timeline describe the experience as predictable; reviewers without that grounding describe weeks 4–8 as anxious or alarming.

Surgeon involvement vs. junior-team execution is a satisfaction differentiator. Korean clinics vary in how much of the procedure the senior surgeon personally performs vs. delegating to junior team members. Reviewers who explicitly asked about and confirmed senior-surgeon involvement throughout describe higher satisfaction at 6 months than reviewers who reported feeling the senior surgeon's involvement was nominal.

Capsular contracture concerns are present but typically not from the primary cohort. Most contracture reports come from cases with prior implants, prior infection, or significant trauma to the implant pocket. Primary-augmentation patients with current-generation implants and good technique report low rates of contracture-related dissatisfaction at 1–5 years.

The filtered breast augmentation reviews show what we have today.

Cautions from clinical practice

Breast augmentation in trained Korean hands has a well-characterized complication profile. The publicly reported issues fall into surgical complications (bleeding, infection, anesthetic) and implant-related issues (capsular contracture, malposition, rupture, BIA-ALCL).

Capsular contracture. The body forms a thin scar capsule around any implant; in some cases the capsule contracts and tightens, distorting implant position and producing firmness, pain, or visible deformity. Reported rates run 5–15% over 10 years across primary cases (lower with newer implants and meticulous technique), higher with revision and after radiation. Newer-generation implants with smooth or nanotextured shells (Motiva SmoothSilk, Mentor Memory Gel) and meticulous pocket-irrigation protocols have reduced rates compared with prior decades. Treatment ranges from observation in mild cases to surgical capsulectomy and implant exchange.

Implant rupture. Modern cohesive gel implants are warranted typically for 10 years; published failure rates run roughly 1% per year cumulatively, with substantial inter-product variability. Cohesive gel rupture is generally non-leaking due to the gel cohesion; saline rupture leads to visible deflation and saline absorption. Routine surveillance for silicone implants is recommended in some regulatory frameworks: the FDA suggests ultrasound or MRI at 5–6 years post-implantation and every 2 years thereafter. Korean clinical practice often favors ultrasound for routine checks (cost and accessibility), with MRI used for cases of suspected rupture or unusual findings. International patients should discuss surveillance with both their Korean surgeon and a home-country provider, and consider following the FDA schedule independently.

Malposition. Implant displacement (lateral, inferior, or symmastia — implant too medial, creating central bulge) requires revision surgery. Reported rates run 1–5% across primary cases; higher with very-large implants relative to tissue cover.

Hematoma and seroma. Acute postoperative bleeding (hematoma) requires return to surgery in 1–3% of primary cases; chronic seroma rates are similar. Both are managed with drainage and meticulous postoperative care.

Infection. Reported rates are under 2% with standard antibiotic prophylaxis and clean technique; severe infection requiring implant removal occurs in under 1%.

Sensation changes. Nipple-areola sensation changes are common (numbness, hypersensitivity, or both) in the first 6–12 months; permanent sensation loss occurs in 5–10%, varying by incision approach (periareolar slightly higher than inframammary).

Animation deformity. With submuscular placement, contracting the pectoralis can produce visible distortion of the implant. Common in submuscular placement; less in dual-plane; absent in subglandular. Aesthetically problematic in some patients (visible during exercise, certain dress positions).

BIA-ALCL. Breast Implant-Associated Anaplastic Large Cell Lymphoma is a recognized rare T-cell lymphoma associated overwhelmingly with macro-textured implants from a previous generation, particularly the Allergan BIOCELL line (globally recalled 2019). Reported lifetime risk for those macro-textured implants ranged from 1:2,000 to 1:30,000 in published cohorts. The published risk with current smooth-shell or nanotextured (Motiva SmoothSilk) implants is statistically near-zero — no analogous risk signal has emerged for these surface technologies in post-market surveillance to date. Patients with current-generation smooth or nanotextured implants should not extrapolate the macro-textured risk figures to their own situation. Patients with implants of any era should be informed about the symptoms (delayed swelling, late seroma, mass) and surveillance approach. Korean clinics generally use current-generation implants; the BIA-ALCL risk profile in current Korean practice differs materially from the historical macro-textured-implant cohort.

BII (Breast Implant Illness). A symptom complex (fatigue, joint pain, brain fog, autoimmune-like signs) reported by some patients with implants. The clinical and regulatory framing remains evolving — there is no specific diagnostic test, the symptom set overlaps with multiple other conditions, and population-level studies have not consistently demonstrated implant causation. Patients reporting BII-pattern symptoms typically improve following implant removal in published case series, though rigorous randomized trial evidence is limited. The Korean clinical conversation about BII has been integrating into consultation discussions, and several Gangnam clinics now offer en-bloc explant services for patients reporting BII-pattern symptoms. Patients should expect a thoughtful discussion at consultation rather than dismissal; clinics that engage substantively with BII are operating in current best-practice mode.

Implant types and placement — the choices that matter

The two highest-impact decisions in primary augmentation are implant type and placement. Both should be discussed in detail at consultation; clinics that don't engage substantively with these decisions are operating in marketing mode rather than surgical-planning mode.

The Korean default for primary augmentation is typically dual-plane placement with inframammary incision using a current-generation cohesive gel implant (Motiva or Mentor). Variations from this default should have a stated reason at consultation.

Cost in Gangnam

Breast augmentation pricing in Korean clinics depends on implant brand, surgeon seniority, hospital tier, and case complexity. The numbers below are clinic-quoted ranges as of 2026:

For comparison: equivalent primary cohesive gel augmentation in the US typically runs $8,000–$15,000 all-in (surgeon, anesthesia, facility, implants); UK £6,000–£10,000; Australia AUD 12,000–20,000. The Korean tier is meaningfully below US/UK pricing while offering technique sophistication and senior-surgeon involvement comparable to those markets. The trip math for breast augmentation favors Korea more than for many K-beauty procedures because the absolute savings ($3,000–$8,000 vs. Western markets) cover travel.

Recovery, day by day

Breast augmentation recovery is meaningful and structured. The procedure-day-to-final-result arc spans 6–12 months; the meaningful phases:

Trip duration: minimum 10-day stay (procedure + 7 days recovery + suture/dressing check before flying); optimal 14-day stay allows for two clinic checkups and a more relaxed recovery. Compression bra is typically worn for 4–6 weeks; switching to underwire bra at 6–8 weeks per surgeon guidance.

The 10 questions to ask in your consultation

Suggested questions for your breast augmentation consultation. The implant-volume, placement, and surgeon-involvement questions are the highest-impact decisions.

1. What volume are you recommending and why? How does that fit my tissue cover and frame? The honest answer references chest dimensions, tissue thickness measurement (skin pinch test), and the relationship between implant volume and projection. "Whatever you want" is not a clinical answer.
2. Which implant brand and shell technology do you recommend, and why? Motiva SmoothSilk vs Mentor MemoryGel vs Sebbin should be discussed with reference to your specific case, not blanket preference.
3. Subglandular, dual-plane, or submuscular placement, and why? Tissue thickness measurement should drive this decision, not blanket clinic preference.
4. Inframammary, periareolar, or transaxillary incision, and why? Inframammary is the Korean default; alternatives should have a stated reason.
5. Who specifically will be in the operating room, and what does the senior surgeon personally do during the case? Korean clinics vary widely in delegation. Ask for explicit answers.
6. What's your reported capsular contracture rate at 3, 5, and 10 years? Specialist clinics with research backgrounds may have published or internal data; high-volume clinics may track outcomes.
7. What's your protocol for capsular contracture management if it develops? The answer should reference massage, observation in mild cases, and surgical capsulectomy in advanced cases.
8. What's your BIA-ALCL surveillance recommendation? What do I do if I notice late seroma or breast changes 5+ years out? The clinic should have a clear answer; absence of one suggests they aren't current on the published guidance.
9. What happens at the 10-year mark? Implant exchange protocol and pricing? Modern implants are not lifetime devices; the long-term plan matters.
10. What's the all-in price including consultation, anesthesia, hospital fee, implants, post-op care, and the 1-year follow-up? Get the full-stack number in writing; itemized line items reveal hidden costs.

Choosing a clinic

Breast augmentation is offered by general plastic surgery clinics across Gangnam; the dedicated breast-and-body specialist subset is smaller but meaningful for higher-complexity cases.

• Board-certified plastic surgeon with high primary-augmentation case volume — typically several hundred annually for premium-tier Korean practices.
• Documented technique and outcome protocols — pocket-irrigation antibiotic protocol, standardized photography, scar-management protocol, capsular contracture surveillance approach.
• Dedicated breast-revision experience — for revision candidates specifically; some clinics handle primary cases well but defer revisions to specialists.
• Anesthesia by board-certified anesthesiologist — not nurse-anesthetist or surgeon-administered, especially for primary cases under general anesthesia.
• Hospital-grade operating facilities — accredited, with overnight observation if needed.
• Transparent implant inventory and product traceability — current-generation Motiva, Mentor, or other documented implants with serial numbers and warranty registration.
• BIA-ALCL surveillance protocol — clinics that engage substantively with this question are operating in current best-practice mode.

The filtered clinic directory shows current matches. For breast augmentation specifically, the shortlist is meaningfully narrower than for general K-beauty because the dedicated-specialist clinic count is smaller; high-quality general plastic surgery clinics also do good augmentation work.

Risks, complications, and what a safe clinic looks like

The published AE rates for primary breast augmentation in trained Korean hands sit roughly here: capsular contracture 5–15% over 10 years; implant rupture cumulative 1% per year; malposition 1–5%; hematoma 1–3%; seroma 1–3%; infection under 2% (severe under 1%); permanent sensation loss 5–10%; animation deformity (variable, more common with submuscular placement); BIA-ALCL extremely rare with current implants (the published 1:2,000 to 1:30,000 figures are specific to recalled macro-textured Allergan BIOCELL, not current generation).

Recognition. Patient-side signals worth knowing: significant unilateral swelling, redness, fever in first 2 weeks (potential infection, requires immediate clinic contact); rapid one-sided enlargement in first 48 hours (potential hematoma); persistent firmness, distortion, or pain at 6+ months (potential capsular contracture); late seroma or unusual swelling years out (BIA-ALCL surveillance — requires specialist evaluation, not just clinic reassurance).

Documentation. Pre-procedure photos from multiple angles in standardized lighting; chest dimensions and tissue thickness measurements; implant brand, size, lot number, and serial; placement and incision approach documented; post-procedure photos at 1 week, 6 weeks, 3 months, 6 months, and 1 year. Clinics that maintain this protocol are operating in outcome-tracking mode.

Safety considerations specific to international medical tourism. The 10-day minimum stay is non-negotiable for primary augmentation because the drainage check, suture removal, and first dressing change must happen at the clinic. Patients who try to compress the recovery to 5–7 days create return-flight complications and risk early-detection misses. The Korean clinic should also have a clear plan for telemedicine follow-up at 3, 6, and 12 months and a specified protocol for revision-trip planning if needed.

Who is a good candidate (and who is not)

Breast augmentation has well-defined candidacy. The ideal candidate is age 22+ (cohesive silicone gel; 18+ saline) in good general health, with realistic expectations about volume and shape, sufficient tissue cover for the planned implant, no active breast disease, and willingness to commit to the long settlement timeline and lifetime monitoring.

Reasons to delay or skip:

• Active pregnancy, breastfeeding, or planned pregnancy in the next 12 months. Pregnancy and breastfeeding change breast size and shape meaningfully; the right time for augmentation is after family-planning is settled, generally 6+ months after weaning.
• Active or unevaluated breast disease. Any breast mass, abnormal mammogram or ultrasound, or strong family history of breast cancer requires evaluation by a breast specialist before elective augmentation.
• Very thin tissue cover (<1.0cm) without willingness to accept submuscular placement. Visibility risk is high in very-thin patients with subglandular or even dual-plane placement.
• Unrealistic volume expectations. A patient requesting 500–800cc in a small frame with thin tissue cover is mismatched in expectation; the procedure cannot defy anatomy without obvious-implant appearance and complication risk.
• Active autoimmune conditions, BII-pattern symptom history, or prior BIA-ALCL. Specialist evaluation required before elective augmentation.
• Severe ptosis without willingness to accept a lift. Augmentation alone in a significantly ptotic breast produces a poor result; lift + implants is the right combination.
• Unwillingness to commit to lifetime monitoring. Implants are not lifetime devices; patients should accept the implication of long-term surveillance and potential exchange.

For patients with prior implants from any era, prior infection or trauma, or significant asymmetry: revision and complex cases benefit from clinics with explicit revision-augmentation experience, not just primary-case volume.

When to travel and how long to stay

Breast augmentation is one of the higher-recovery K-beauty procedures and requires a meaningfully longer stay than non-surgical or smaller-surgery cases.

Minimum: 10 days. Procedure day, 7 days recovery (with first clinic check at day 1–2 and second at day 7–10), suture removal, and clearance to fly. Tight but feasible.

Optimal: 14 days. Procedure + 12 days recovery + 2–3 clinic checks + dressing changes + a more relaxed recovery before flying. Most international patients choose this; the 14-day stay reduces the chance of missing an early-detection issue.

Long-arc follow-up: 3, 6, and 12 month checks, typically managed via remote photo submission for international patients. Some clinics specifically schedule the 1-year follow-up for an in-person visit; this is optional for most patients but recommended if any early-recovery concerns arose.

Combination trips: Breast augmentation generally should not be combined with other significant surgical procedures (rhinoplasty, facial contouring) in the same trip due to cumulative recovery burden. Combining with non-surgical procedures (botox, filler before chest surgery, light skin treatments after recovery) is reasonable but should be staged in the trip schedule.

Touch-up sessions: If revision becomes needed (capsular contracture, malposition, asymmetry refinement), typically scheduled 6–18 months out depending on issue severity. Most revisions require a second separate trip.

Tax refund, cash discount, and seasonal deals

Three layers of price reduction stack at most clinics. Breast augmentation is a high-absolute-amount procedure, so percentage savings translate to meaningful dollar savings:

VAT refund. Up to 10% of the procedure cost, recoverable at Incheon Airport for foreigners on tourist visas — but only at clinics registered with Korea's Medical Tourist Tax Refund program. Cosmetic breast augmentation generally qualifies; reconstruction or medically-coded cases sometimes don't. Either Global Tax Free or KT Tourism Tax Refund handles most refunds. The tax refund calculator shows what you'll actually recover after fees.

Cash discount. Typically 5–10%. On a ₩10,000,000 ($7,600) primary case, this is ₩500,000–₩1,000,000 ($380–$760) in savings.

Seasonal promotions. Less common for breast augmentation than for non-surgical procedures, since clinical capacity and surgeon scheduling drive the calendar more than promotional cycles. Some clinics offer modest discounts for early-year scheduling or for combined procedures (lift + augmentation, fat grafting + implants).

Currency exchange: Pricing in KRW is typically locked at booking. Patients booking 3–6 months ahead can occasionally benefit from favorable USD-to-KRW movement; the inverse risk is also real.

Alternatives to consider instead

Breast augmentation is the right answer for cosmetic volume increase with predictable shape. If your case is something else, consider these alternatives:

• Modest volume enhancement without implants. Fat grafting (autologous fat transfer from another body region to the breast) provides a modest volume increase (typically half a cup size, occasionally one cup) with permanent results for surviving fat (typical survival 50–70%). No implant, no implant-related complications, but limited maximum volume per session.
• Significant ptosis with adequate volume. Mastopexy (breast lift) addresses position without volume change. The right answer for patients with adequate volume and significant sag.
• Significant ptosis with volume loss. Augmentation-mastopexy (lift + implants) addresses both. More complex than either alone.
• Asymmetry correction. May involve different-volume implants on each side, plus possible reduction or lift on one side. Requires careful planning.
• Reduction. Reduction mammoplasty is a different procedure for volume excess; not a relabeling of augmentation.
• Non-surgical alternatives. Push-up bras, compression products, or non-surgical "breast enhancement" creams and devices have minimal anatomical effect; they should not be confused with augmentation.
• Non-treatment. Some patients reassess after consultation and choose to live with their natural anatomy. This is a legitimate outcome.

A serious breast augmentation consultation will sometimes recommend fat grafting only, augmentation-mastopexy combination, asymmetry-specific planning, or staged approaches. That signals an outcome-focused practice rather than a volume conveyor.

The bottom line

The case for Gangnam for breast augmentation rests on a combination of technique sophistication, surgeon experience, and meaningful price differential vs. Western markets. A typical primary cohesive silicone gel case in Korea runs $5,300–$11,500 vs. $8,000–$15,000+ in the US; the absolute savings of $3,000–$8,000 cover travel from most origins. The current-generation implant brands (Motiva SmoothSilk, Mentor MemoryGel) used at Korean premium-tier clinics are the same global standards available in any major Western market, and the surgical technique conventions (dual-plane placement, inframammary incision, pocket irrigation protocols) align with current international best practice.

The case against is that breast augmentation is one of the most recovery-intensive K-beauty procedures, with a 10-day minimum stay and a 6–12 month settlement and outcome timeline. Patients who can't commit to the full timeline or who can't accommodate a longer recovery trip may be better served by a local provider. The long-distance follow-up (months 3, 6, 12) requires telemedicine cooperation and limits the clinic's ability to catch early issues that an in-person follow-up would identify. For patients with prior complications, complex anatomy, or revision needs, the local-provider option may also offer continuity advantages that international practice can't match.

The patients for whom Gangnam breast augmentation is most clearly the right call are those with stable health and reasonable expectations; sufficient time for the 10–14 day stay; primary-case rather than complex-revision indications; willingness to accept the long-distance follow-up model; and origins where flight cost is not prohibitive relative to the $3,000–$8,000 in absolute savings vs. Western markets. For patients in the Asia-Pacific region with shorter travel times, Korea is often the dominant cost-quality choice.

For revision candidates: revision augmentation is more complex, more expensive, and requires more specialist experience than primary cases. Korean clinics with explicit revision experience exist and produce good outcomes; clinics that primarily handle primary cases should be evaluated more carefully for revision indications.

If you do come, four practical notes. First, plan for the 14-day optimal stay rather than the 10-day minimum if your schedule allows; the second clinical check at day 5–7 and the more relaxed recovery materially reduce risk of early-detection issues. Second, get the implant brand, size, lot number, and serial recorded in your medical records and warranty registration; this matters for any future revision or surveillance. Third, plan for the 6–12 month settlement timeline mentally — the 6-week result is not the final result. Fourth, the BIA-ALCL surveillance discussion is part of the procedure, not optional; clinics that don't engage substantively with this question are not operating in current best-practice mode.

Breast augmentation is one of the K-beauty procedures where surgical technique, implant selection, and long-term monitoring all matter genuinely for outcome. The consultation conversation that matters most is the matching of your specific anatomy and expectations to the implant and placement choice; Korean surgeons typically engage substantively with this when given the opportunity, and the resulting outcomes for well-matched patients are competitive with any global market.